secwatch.observer — SEC 8-K summary
======================================

Issuer:     Longeveron Inc. (LGVN)
CIK:        0001721484
Form:       8-K
Filed at:   2026-05-08T23:59:59+00:00
Accession:  0001213900-26-053902
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Longeveron FDA Type C meeting: ELPIS II trial no longer deemed pivotal; top-line data due Aug 2026
--------------------------------------------------------------------------------

- FDA stated RVEF is not an appropriate primary endpoint; no new endpoint can be agreed while trial blinded due to NIH interim analysis.
- ELPIS II is no longer referred to as pivotal by FDA, reversing prior 2024 discussion.
- FDA willing to meet after trial completion; objective measures (mortality, transplant, MACE) could support efficacy.
- Company will submit a Sponsor Statistical Analysis Plan with composite primary endpoint for FDA review.
- Top-line Phase 2b results for laromestrocel in HLHS still expected in August 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1721484/000121390026053902/0001213900-26-053902-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1721484/000121390026053902/ea0289853-8k_longeveron.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-053902

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer